ELAN Stock Analysis: Buy, Sell, or Hold?
ELAN - Elanco Animal Health Incorporated Common Stock
$23.97
0.41 (1.74%)
▲
5d:
+1.27%
30d:
-3.27%
90d:
+12.43%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ELAN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ELAN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$38.84
Based on 8.1% avg growth
INTRINSIC VALUE TODAY
$24.12
0.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 20.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ELAN is currently trading at $23.97, which is considered slightly low relative to its 30-day fair value range of $23.35 to $26.01. The stock's valuation (Forward PE: 19.0) is in line with its historical norms (20.9). Remarkably, the market is currently pricing in an annual earnings decline of 3.2% over the next few years. This pessimistic expectation contrasts with the company's recent 440.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ELAN is in a uptrend. The price is approaching resistance at $24.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $31.21 (+30.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ELAN is in a uptrend. The price is approaching resistance at $24.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 53/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $31.21 (+30.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$23.35 -
$26.01
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding ELAN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (53/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.2% below Wall St target ($31.21)
- NEUTRAL: Bottoming setup forming (53/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$23.35 -
$26.01
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$21.32
Resistance Level
$24.57
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.96
Wall Street Target
$31.21
(+30.2%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
440.5%
Profit Margin
-4.0%
Valuation Discount vs History
-3.2% cheaper
PE vs Historical
19.0 vs 20.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.2%
(market-implied from PE analysis)
1-Year Target
$23.20
(-3%)
2-Year Target
$22.46
(-6%)
3-Year Target
$21.74
(-9%)
3-Yr Target (if PE normalizes)
(PE: 19→21)
$23.96
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 12.1%)
$35.76
(+49%)
Base:
(SPY PE: 19.0, Growth: 12.1%)
$33.79
(+41%)
Bear:
(PE: 16.1, Growth: 12.1%)
$28.72
(+20%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.0 to 20.9
Stabilization Target:
$26.42
(+10.2%)
PE Expansion Potential:
+10.2%
Share & Embed Analysis
Last updated: August 24, 2026 8:40 AM ET
Data refreshes hourly during market hours. Next update: 9:40 AM
Data refreshes hourly during market hours. Next update: 9:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELAN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced ELAN Option Strategies
Professional options setups generated by AI based on today's ELAN price and gamma walls.
